Browsing Tag
Cancer immunotherapy
24 posts
TuHURA Biosciences extends runway into 2028 as HURA investors wait for Merkel cell carcinoma data
TuHURA has bought time with a $50m facility. The harder test is whether IFx-2.0 can deliver before HURA investors lose patience.
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.
OSR Holdings (NASDAQ: OSRH) explores royalty-driven licensing for Vaximm’s cancer therapy
Vaximm may license its oral cancer therapy VXM01 in a deal worth up to $815M. Find out how OSR Holdings plans to turn this into a royalty-driven biotech play.
Vaximm AG advances VXM01 strategy with BCM Europe term sheet offering US$20m upfront and US$815m upside
Learn how Vaximm AG’s new term sheet with BCM Europe sets the stage for a US$20M upfront license deal and up to US$815M in milestones.
Why OSR Holdings (NASDAQ: OSRH) chose its scientific founder to lead Vaximm’s next immunotherapy chapter
OSR Holdings appoints scientific founder Dr. Andreas Niethammer as CEO of Vaximm AG to lead next-gen cancer immunotherapy strategy. Read more.
Ernexa Therapeutics (NASDAQ: ERNA) surges 68% after Cellipont deal to advance ovarian cancer cell therapy ERNA‑101
Ernexa Therapeutics stock jumps 68% after partnering with Cellipont to manufacture its ovarian cancer cell therapy ERNA-101. Learn what’s driving investor interest.
HanchorBio and Henlius sign $202m licensing deal for HCB101 to expand immuno-oncology access across Asia and MENA
HanchorBio Inc. (7827.TWO), a clinical-stage immunotherapy innovator, has entered a major licensing agreement with Shanghai Henlius Biotech Inc.…
Percheron Therapeutics (ASX: PER) licenses HMBD-002 cancer drug from Hummingbird in oncology pivot
Percheron Therapeutics acquires global rights to phase II-ready cancer drug HMBD-002 from Hummingbird Bioscience. Learn what this means for investors.
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a…
CStone Pharmaceuticals advances CS2009 clinical trial, targeting multi-billion-dollar immunotherapy market
CStone Pharmaceuticals has officially commenced the Phase I clinical trial for CS2009, a cutting-edge PD-1/VEGF/CTLA-4 trispecific antibody, marking…